BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.
Share
Why It Matters
An expert still likes Acumen but thinks its stock is worth much less money now. This hints the company faces big challenges, even though the expert still believes in it long term.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.